Skip to main content
Log in

Ovulationshemmer bei Risikogruppen

Contraception in patients with risk factors

  • Zum Thema
  • Published:
Der Gynäkologe Aims and scope

Zusammenfassung

In den meisten Fällen treten schwerwiegende Nebenwirkungen unter der Behandlung mit Ovulationshemmern bei Frauen auf, die aufgrund genetischer oder erworbener Faktoren ein erhöhtes Risiko für die Entwicklung bestimmter Erkrankungen haben. Mit Hilfe einer sorgfältigen Eigen- und Familienanamnese sowie spezifischer Laboruntersuchungen lässt sich häufig eine bestimmte Prädisposition erkennen und das mit der Anwendung von oralen Kontrazeptiva verbundene individuelle Risiko abschätzen. Der vorliegende Beitrag beschreibt die möglichen Auswirkungen einer Behandlung mit Ovulationshemmern bei Frauen mit Thrombophilie, Herz-Kreislauf-Erkrankungen, Diabetes mellitus, Dyslipidämien, Über- oder Untergewicht, Tumoren, psychiatrischen und neurologischen Erkrankungen sowie Autoimmunerkrankungen. Entsprechend den vorliegenden Schädigungen und Risikofaktoren werden die für die Empfängnisverhütung zur Verfügung stehenden hormonalen Methoden und nichthormonalen Alternativen erläutert und deren Vor- und Nachteile diskutiert.

Abstract

Severe adverse effects during the use of ovulation inhibitors occur mostly in women who have an elevated risk for the development of certain diseases owing to hereditary or acquired factors. By means of a careful personal or family history analysis as well as specific laboratory examinations, an existing predisposition may frequently be diagnosed and the individual risk associated with the use of oral contraceptive inhibitors may be estimated. The present contribution describes the potential effects of treatment with ovulation inhibitors on women with thrombophilia, cardiovascular disease, diabetes mellitus, dyslipidemia, overweight or underweight, tumors, psychiatric and neurological diseases and autoimmune disease. The hormonal methods and non-hormonal alternatives available for contraception are elucidated according to existing lesions and risk factors and the advantages and disadvantages are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Alonso A, Jick SS, Olek MJ et al. (2005) Recent use of oral contraceptives and the risk of multiple sclerosis. Arch Neurol 62: 1362–1365

    Article  PubMed  Google Scholar 

  2. Baillargeon JP, McClish DK, Essah PA et al. (2005) Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 90: 3863–3870

    Article  PubMed  Google Scholar 

  3. Birkhäuser M, Braendle W, Keller PJ (2006) Empfehlungen zur hormonalen Kontrazeption. 34. Arbeitstreffen des „Zürcher Gesprächskreises“ April 2005. Gynäkol Geburtsh Rundsch 46: 58–63

    Google Scholar 

  4. Bloemenkamp KWM (2005) Epidemiology of oral contraceptive related thrombosis. Thromb Res 115S: 1–6

    Google Scholar 

  5. Breckwoldt M, Hösli I, Hufnagel A et al. (1999) Einfluss von Östrogenen und Gestagenen auf neurologische Erkrankungen. Frauenarzt 40: 1148–1152

    Google Scholar 

  6. Chan WS, Ray J, Wai EK et al. (2004) Risk of stroke in women exposed to low-dose oral contraceptives. A critical evaluation of the evidence. Arch Intern Med 164: 741–747

    Article  PubMed  Google Scholar 

  7. Conard J, Plu-Bureau G, Bahi N et al. (2004) Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception 70: 437–441

    Article  PubMed  Google Scholar 

  8. Curtis KM, Mohllajee AP, Peterson HB (2006) Use of combined oral contraceptives among women with migraine and nonmigrainous headaches: a systematic review. Contraception 73: 189–194

    Article  PubMed  Google Scholar 

  9. Etminan M, Takkouche B, Isorna FC et al. (2005) Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 330: 63–65

    Article  PubMed  Google Scholar 

  10. Gomes MPV, Deitcher SR (2004) Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy. Arch Intern Med 164: 1965–1976

    Article  PubMed  Google Scholar 

  11. Heinemann LAJ, Assmann A, DoMinh T et al. (1999) Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Eur J Contracept Reprod Health Care 4: 67–73

    PubMed  Google Scholar 

  12. Herkert O, Kuhl H, Sandow J et al. (2001) Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression. Role of the glucocorticoid receptor. Circulation 104: 2826–2831

    PubMed  Google Scholar 

  13. Karlson EW, Mandl LA, Hankinson SE et al. (2004) Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis? Arthr Rheum 50: 3458–3467

    Article  Google Scholar 

  14. Khader YS, Rice J, John L et al. (2003) Oral contraceptive use and the risk of myocardial infarction: a meta-analysis. Contraception 68: 11–17

    Article  PubMed  Google Scholar 

  15. Kuhl H, Jung-Hoffmann C (1999) Kontrazeption. Thieme, Stuttgart, S 56–65

  16. Kuhnz W, Heuner A, Hümpel M et al. (1997) In vivo conversion of norethisterone and norethisterone acetate to ethinyl estradiol in postmenopausal women. Contraception 56: 379–385

    Google Scholar 

  17. Mok CC, Wong RWS, Lau CS (1999) Ovarian failure and flares of systemic lupus erythematodes. Arthr Rheum 42: 1274–1280

    Article  Google Scholar 

  18. Oinonen KA, Mazmanian D (2002) To what extent do oral contraceptives influence mood and affect? J Affect Disord 70: 229–240

    Article  PubMed  Google Scholar 

  19. Rosendaal FR (1997) Thrombosis in the young: epidemiology and risk factors on venous thrombosis. Thromb Haemost 78: 1–6

    Google Scholar 

  20. Rosendaal FR (1996) Oral contraceptives and screening for Factor V Leiden. Thromb Haemost 75: 520–526

    Google Scholar 

  21. Shawe J, Lawrenson R (2003) Hormonal contraception in women with diabetes mellitus – special considerations. Treat Endocrinol 2: 321–330

    Article  PubMed  Google Scholar 

  22. Tans G, Bouma BN, Büller HR et al. (2003) Changes of hemostatic variables during oral contraceptive use. Sem Vasc Med 3: 61–68

    Article  Google Scholar 

  23. Vasilakis C, Jick H, Melero-Montes M (1999) Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 354: 1610–1611

    Article  Google Scholar 

  24. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1998) Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Contraception 57: 315–324

    Article  PubMed  Google Scholar 

  25. Wiegratz I, Kuhl H (2002) Managing cutaneous manifestations of hyperandrogenic disorders. The role of oral contraceptives. Treat Endocrinol 1: 373–386

    Article  Google Scholar 

Download references

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to H. Kuhl.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wiegratz, I., Kuhl, H. Ovulationshemmer bei Risikogruppen. Gynäkologe 39, 696–706 (2006). https://doi.org/10.1007/s00129-006-1880-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00129-006-1880-8

Schlüsselwörter

Keywords

Navigation